CSL Limited has welcomed the Therapeutic Goods Administration approval of its Hizentra [normal immunoglobulin (human) 20% subcutaneous injection] for the treatment of patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP).
CIDP is a rare autoimmune disorder that affects the peripheral nerves and may cause permanent nerve damage, with the approval of Hizentra meaning Australian patients who previously had to visit a hospital to receive IV treatment will instead be able to self-administer subcutaneous immunoglobulin therapy at home.
The above article was sent to subscribers in Pharmacy Daily's issue from 18 Sep 18
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 18 Sep 18
